Cancer Genomic Profiling and Somatic Mutations
This dataset provides comprehensive cancer genomic profiling results, detailing somatic mutations, driver genes, actionable mutations, tumor mutational burden (TMB), microsatellite instability (MSI), and therapeutic targets for each tumor sample. It is ideal for translational research, biomarker discovery, and precision oncology applications, enabling advanced analytics and clinical decision support.
Sample rows
preview · 8 of 100 rows · all 14 columns| sample_idstring | genomic_platformstring | somatic_mutation_countinteger | clinical_trial_eligibilityboolean | driver_gene_liststring | patient_idstring | tumor_typestring | collection_datedate | actionable_mutation_liststring | tmb_scorefloat | msi_statusstring | therapeutic_target_liststring | report_datedate | notesstring |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMP-00001 | Illumina NovaSeq | 43 | true | EGFR,TP53 | PAT-012A | lung adenocarcinoma | 2022-02-11 | EGFR exon19del | 6.7 | MSS | EGFR | 2022-02-17 | EGFR mutation detected; eligible for targeted therapy. |
| SMP-00002 | Ion Torrent | 12 | false | PIK3CA,TP53 | PAT-003B | breast carcinoma | 2021-07-23 | blank | 2.1 | MSS | blank | 2021-07-28 | Low mutation burden; no actionable findings. |
| SMP-00003 | Illumina HiSeq | 98 | true | KRAS,APC | PAT-031C | colorectal adenocarcinoma | 2023-01-15 | KRAS G12D | 12.4 | MSI-High | KRAS | 2023-01-20 | High MSI; eligible for immunotherapy. |
| SMP-00004 | Thermo Fisher Ion S5 | 18 | false | KRAS | PAT-004D | pancreatic adenocarcinoma | 2021-09-05 | blank | 3 | MSS | blank | 2021-09-11 | KRAS mutation common; no actionable variants. |
| SMP-00005 | Illumina NextSeq | 8 | false | TP53 | PAT-014E | prostate carcinoma | 2022-04-10 | blank | 1.2 | MSS | blank | 2022-04-14 | No actionable findings. |
| SMP-00006 | Illumina NovaSeq | 34 | true | BRAF,NRAS | PAT-057F | melanoma | 2022-12-18 | BRAF V600E | 9.7 | MSS | BRAF | 2022-12-22 | BRAF V600E mutation detected; eligible for BRAF inhibitors. |
| SMP-00007 | Illumina HiSeq | 16 | false | IDH1,TP53 | PAT-038G | glioblastoma | 2020-06-30 | blank | 2.8 | Unknown | blank | 2020-07-06 | IDH1 mutation detected; MSI status inconclusive. |
| SMP-00008 | Ion Torrent | 52 | true | TP53,FGFR1 | PAT-019H | lung squamous cell carcinoma | 2023-03-04 | FGFR1 amplification | 10.5 | MSS | FGFR1 | 2023-03-10 | FGFR1 amplification detected; eligible for FGFR inhibitors. |
| SMP-00009 | Illumina NextSeq | 20 | false | VHL | PAT-022I | renal cell carcinoma | 2020-11-21 | blank | 3.3 | MSS | blank | 2020-11-26 | VHL mutation detected; no actionable variants. |
| SMP-00010 | Illumina NovaSeq | 65 | true | PTEN,PIK3CA | PAT-008J | endometrial carcinoma | 2021-01-13 | PIK3CA E545K | 13.2 | MSI-Low | PIK3CA | 2021-01-19 | PIK3CA mutation detected; candidate for targeted therapy. |
| SMP-00011 | Illumina HiSeq | 27 | true | BRCA1,TP53 | PAT-032K | ovarian carcinoma | 2022-06-28 | BRCA1 deletion | 7.8 | MSS | BRCA1 | 2022-07-01 | BRCA1 deletion detected; PARP inhibitor eligibility. |
| SMP-00012 | Ion Torrent | 44 | false | CDH1,TP53 | PAT-045L | gastric adenocarcinoma | 2020-10-02 | blank | 6.2 | MSI-Low | blank | 2020-10-07 | CDH1 mutation detected; no actionable findings. |
| SMP-00013 | Illumina NovaSeq | 39 | true | EGFR,KRAS | PAT-012A | lung adenocarcinoma | 2023-05-02 | EGFR L858R | 5.9 | MSS | EGFR | 2023-05-09 | EGFR L858R mutation detected; sensitive to EGFR inhibitors. |
| SMP-00014 | Illumina NextSeq | 24 | true | FGFR3,TP53 | PAT-052M | bladder carcinoma | 2021-05-18 | FGFR3 S249C | 8.5 | MSS | FGFR3 | 2021-05-22 | FGFR3 S249C mutation detected; FGFR inhibitor eligibility. |
| SMP-00015 | Ion Torrent | 15 | false | TP53,PIK3CA | PAT-067N | breast carcinoma | 2022-09-26 | blank | 2.5 | MSS | blank | 2022-10-03 | No actionable findings. |
| SMP-00016 | Illumina HiSeq | 112 | true | APC,KRAS | PAT-041O | colorectal adenocarcinoma | 2023-04-14 | KRAS G13D | 15.6 | MSI-High | KRAS | 2023-04-17 | High mutational burden; candidate for immunotherapy. |
| SMP-00017 | Thermo Fisher Ion S5 | 58 | false | TP53,FGFR1 | PAT-039P | lung squamous cell carcinoma | 2022-07-30 | blank | 11.1 | MSS | blank | 2022-08-03 | No actionable variants detected. |
| SMP-00018 | Illumina NovaSeq | 22 | true | KRAS | PAT-053Q | pancreatic adenocarcinoma | 2021-02-09 | KRAS G12V | 4.1 | MSS | KRAS | 2021-02-16 | KRAS G12V mutation; clinical trial eligibility for targeted therapy. |
| SMP-00019 | Illumina HiSeq | 41 | true | BRAF | PAT-058R | melanoma | 2023-02-15 | BRAF V600K | 8.9 | MSS | BRAF | 2023-02-20 | BRAF V600K mutation; eligible for BRAF-targeted therapy. |
| SMP-00020 | Ion Torrent | 17 | false | VHL | PAT-016S | renal cell carcinoma | 2022-03-28 | blank | 2.7 | Unknown | blank | 2022-04-02 | VHL mutation detected. |
What the 100 rows show
from the 100-row sampleIllumina HiSeq (genomic platform) stands out: mean somatic_
- 43%clinical_
trial_ eligibility = true - 25median somatic_
mutation_ count - 4msi statuses
- 21tumor types
- 6.3median tmb_
score
Median 25, from 5 to 112.
- string 9
- integer 1
- float 1
- date 2
- boolean 1
Columns
14 columns in four groups| column | type | description | example |
|---|---|---|---|
| Text 9 columns | |||
sample_id | string | Unique identifier for the tumor sample analyzed.unique | SMP-00001 |
patient_id | string | Unique identifier for the patient from whom the sample was collected. | PAT-012A |
tumor_type | string | Type or classification of the tumor (e.g., lung adenocarcinoma, breast carcinoma). | lung adenocarcinoma |
driver_gene_list | string | Comma-separated list of driver genes identified in the sample.optional | EGFR,TP53 |
actionable_mutation_list | string | Comma-separated list of actionable mutations detected in the sample.optional | EGFR exon19del |
msi_status | string | Microsatellite instability status (e.g., MSI-High, MSI-Low, MSS).MSI-High · MSI-Low · MSS · Unknown | MSS |
therapeutic_target_list | string | Comma-separated list of therapeutic targets identified in the sample.optional | EGFR |
genomic_platform | string | Sequencing platform or technology used for genomic profiling (e.g., Illumina, Ion Torrent).7 platforms · optional | Illumina NovaSeq |
notes | string | Additional comments or notes regarding the sample or findings.optional | No actionable findings. |
| Numbers 2 columns | |||
somatic_mutation_count | integer | Total number of somatic mutations identified in the sample.0 or more | 43 |
tmb_score | float | Tumor Mutational Burden (TMB) score, typically measured as mutations per megabase.0 or more | 6.7 |
| Dates and times 2 columns | |||
collection_date | date | Date when the tumor sample was collected. | 2022-02-11 |
report_date | date | Date when the genomic profiling report was generated.optional | 2022-02-17 |
| True or false 1 column | |||
clinical_trial_eligibility | boolean | Indicates if the patient/sample is eligible for clinical trials based on genomic findings.optional | true |
Use it for
A healthcare dashboard
The clinical_
trial_ eligibility rate, somatic_ mutation_ count by genomic_ platform and a breakdown of driver_ gene_ list. Excel, Power BI or Tableau. Why do the 14 Illumina HiSeq rows have a mean somatic_
mutation_ count of 55.6? A root-cause class exercise
Hand out the rows and one question. The answer is in the data, not in the brief.
- Samples100SMP-0000143Illumina…SMP-0000212Ion Torr…SMP-0000398Illumina…
A software demo
Believable samples with patient_
id, tumor_ type and collection_ date to fill a screen in front of a buyer.
This dataset100 rows14 columns
Yours1,000 rows14 columns
blueprint · cancer-genomic-profiling-and-somatic-mutations
Behind this dataset
Same schema. As many rows as you need.
These 100 rows came out of a blueprint — 14 columns with generation rules behind each one. Open it in Data Factory to retune a column, add your own, wire in foreign keys, and run it at the size you actually need.
Rules it was built with
- Tumor sample ID unique
- Tumor type and primary site
- Matched normal sample for germline filtering
- Panel sequencing vs whole exome vs whole genome
- Driver mutations in oncogenes (KRAS, EGFR, BRAF, etc.)
- Tumor suppressor gene mutations (TP53, PTEN, RB1)
- Actionable mutations with FDA-approved therapies
- Tumor mutational burden (TMB): mutations per megabase
Open the blueprint in Data Factory
1 credit per row. Preview 20 rows free. Buy rows for the full run.
- Exports
- CSV, JSON, JSONL, Parquet, SQL, Excel, TSV, XML
- Licence
- yours to use, including commercially
- API slug
- cancer-genomic-profiling-and-somatic-mutations